BR9814015A - Processo para preparação de produtos sólidos instantaneamente solúveis para uso farmacêutico, ditos produtos, método de prevenção e tratamento - Google Patents

Processo para preparação de produtos sólidos instantaneamente solúveis para uso farmacêutico, ditos produtos, método de prevenção e tratamento

Info

Publication number
BR9814015A
BR9814015A BR9814015-9A BR9814015A BR9814015A BR 9814015 A BR9814015 A BR 9814015A BR 9814015 A BR9814015 A BR 9814015A BR 9814015 A BR9814015 A BR 9814015A
Authority
BR
Brazil
Prior art keywords
products
cyclodextrin
prevention
treatment
pharmaceutical use
Prior art date
Application number
BR9814015-9A
Other languages
English (en)
Inventor
Joseph M Geczy
Original Assignee
Thissen Laboratoires S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thissen Laboratoires S A filed Critical Thissen Laboratoires S A
Publication of BR9814015A publication Critical patent/BR9814015A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

"PROCESSO PARA PREPARAçãO DE PRODUTOS SóLIDOS INSTANTANEAMENTE SOLúVEIS PARA USO FARMACêUTICO, DITOS PRODUTOS, MéTODO DE PREVENçãO E TRATAMENTO". A presente invenção refere-se a composições farmacêuticas sólidas solúveis em água e suas soluções em solventes aquosos, ditas composições contendo a). como ingrediente ativo um taxóide amorfo finamente disperso preferivelmente liofilizado e com extensa área superficial, tal como paclitaxel ou docetaxel, seus sais e seus hidratos ou solvatos polimórficos, tal como solvatos formados com etanol e b). acetil-y-ciclodextrina ou hidroxi-propil-ß-ciclodextrina (ciclodextrina) amorfa finamente dispersa, preferivelmente liofilizada e com externa área superficial, por meio do que a relação de peso de dito taxóide: dita ciclodextrina varia entre 1 : 25 e 1 : 400; c). e opcionalmente outros materiais auxiliares solúveis em água comuns em fármacos para fins parenterais.
BR9814015-9A 1997-11-10 1998-11-09 Processo para preparação de produtos sólidos instantaneamente solúveis para uso farmacêutico, ditos produtos, método de prevenção e tratamento BR9814015A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU9701945A HUP9701945A3 (en) 1997-11-10 1997-11-10 Pharmaceutical composition for injection containing cyclodextrin and taxoids
PCT/HU1998/000097 WO1999024073A1 (en) 1997-11-10 1998-11-09 Pharmaceutical compositions containing cyclodextrins and taxoids

Publications (1)

Publication Number Publication Date
BR9814015A true BR9814015A (pt) 2000-09-26

Family

ID=89995733

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9814015-9A BR9814015A (pt) 1997-11-10 1998-11-09 Processo para preparação de produtos sólidos instantaneamente solúveis para uso farmacêutico, ditos produtos, método de prevenção e tratamento

Country Status (19)

Country Link
US (1) US7671042B2 (pt)
EP (1) EP1059942B1 (pt)
JP (1) JP3656550B2 (pt)
KR (1) KR100607391B1 (pt)
CN (1) CN1222321C (pt)
AR (1) AR015482A1 (pt)
AT (1) ATE387916T1 (pt)
AU (1) AU742036B2 (pt)
BR (1) BR9814015A (pt)
CA (1) CA2309326C (pt)
DE (1) DE69839224T2 (pt)
EA (1) EA002776B1 (pt)
HU (1) HUP9701945A3 (pt)
IL (1) IL135990A0 (pt)
NO (1) NO329382B1 (pt)
NZ (1) NZ504098A (pt)
PL (1) PL199652B1 (pt)
WO (1) WO1999024073A1 (pt)
ZA (1) ZA989779B (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020300A1 (es) 2000-08-22 2002-05-10 Pharmacia Corp Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco
WO2003015828A1 (en) * 2001-08-20 2003-02-27 Boehringer Ingelheim Pharmaceuticals, Inc. Parenteral formulations of 1-(5-tert-butyl-2-p-tolyl-2h-pryrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea and a cyclodextrin
CN100384865C (zh) * 2001-11-02 2008-04-30 嵌入治疗公司 用于rna干扰的治疗用途的方法及组合物
US20050255164A1 (en) * 2002-08-15 2005-11-17 Yunging Liu Solid nano pharmaceutical formulation and preparation method thereof
AR054215A1 (es) 2006-01-20 2007-06-13 Eriochem Sa Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit
CN101020059B (zh) * 2006-02-15 2011-01-05 中国科学院上海药物研究所 一种含多烯紫杉醇类物质的药物组合物及其制备方法
KR100917809B1 (ko) * 2006-05-22 2009-09-18 에스케이케미칼주식회사 우수한 저장안정성을 갖는 도세탁셀 함유 주사제 조성물
KR100917810B1 (ko) * 2006-06-02 2009-09-18 에스케이케미칼주식회사 저장안정성이 우수한 파클리탁셀 함유 주사제 조성물
WO2007142440A1 (en) * 2006-06-02 2007-12-13 Sk Chemicals Co., Ltd. Stable pharmaceutical composition containing paclitaxel and a method of manufacturing the same
CN100411688C (zh) * 2006-09-12 2008-08-20 南京师范大学 含有环糊精/多烯紫杉醇包合物的药物组合物及其制备方法
CN100486645C (zh) 2006-09-12 2009-05-13 南京师范大学 含有环糊精紫杉醇包合物的药物组合物及其制备方法
WO2008092084A2 (en) 2007-01-26 2008-07-31 Centocor, Inc. Injectable non-aqueous suspension with high concentration of therapeutic agent
US20080262078A1 (en) * 2007-04-20 2008-10-23 Namdeo Alok B Pharmaceutical Compositions
WO2009002425A2 (en) * 2007-06-22 2008-12-31 Scidose Llc Solubilized formulation of docetaxel without tween 80
US20090087460A1 (en) * 2007-10-02 2009-04-02 Hamamatsu Photonics K.K. Solid composition, microparticles, microparticle dispersion liquid, and manufacturing methods for these
AR063111A1 (es) 2007-10-03 2008-12-30 Eriochem Sa Una formulacion farmaceutica de taxano
KR101478779B1 (ko) * 2007-11-22 2015-01-05 에스케이케미칼주식회사 재수화시간이 향상된 택산 유도체 함유 동결건조 조성물 및이의 제조방법
KR101502533B1 (ko) * 2007-11-22 2015-03-13 에스케이케미칼주식회사 우수한 안정성을 갖는 택산 유도체 함유 주사제용동결건조 조성물 및 이의 제조방법
EP2106786A1 (de) * 2008-04-04 2009-10-07 Roewer, Norbert, Univ.-Prof. Dr. med. Pharmazeutische Zubereitung mit permethyliertem Cyclodextrin
US8912228B2 (en) 2009-10-19 2014-12-16 Scidose Llc Docetaxel formulations with lipoic acid
KR20120130740A (ko) * 2011-05-23 2012-12-03 에스케이케미칼주식회사 도세탁셀을 함유하는 액상 주사용 조성물
US11406595B2 (en) * 2012-05-21 2022-08-09 University Of Maryland, College Park Highly stable colloid from aqueous solutions of small organic molecules
WO2014075935A1 (de) 2012-11-15 2014-05-22 Sapiotec Gmbh Delphinidinkomplex als antiphlogistischer oder immunsuppressiver wirkstoff
CN104936601A (zh) 2012-12-11 2015-09-23 赛博尔泰克股份公司 用于对抗黑色素瘤细胞的飞燕草素
CN105823810A (zh) * 2016-01-04 2016-08-03 杭州电子科技大学 紫杉醇化疗效果检测装置及检测方法
KR101829705B1 (ko) * 2016-09-21 2018-02-19 씨제이헬스케어 주식회사 안정성이 향상된 주사용 조성물
KR102262743B1 (ko) 2017-07-07 2021-06-09 에이치케이이노엔 주식회사 주사용 조성물
CN110755371B (zh) 2018-07-25 2021-08-31 比卡生物科技(广州)有限公司 一种注射用多西他赛组合物及其制备方法
JP7802829B2 (ja) * 2021-05-26 2026-01-20 デウン ファーマシューティカル カンパニー リミテッド 1-(5-(2,4-ジフルオロフェニル)-1-((3-フルオロフェニル)スルホニル)-4-メトキシ-1h-ピロール-3-イル)-n-メチルメタンアミンを含む新規な注射用製剤
CN115960834B (zh) * 2023-03-07 2023-06-09 浙江省肿瘤医院 一种pd-1/ptx联合pd-1耐药模型建立的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602112A (en) * 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
JPH06157330A (ja) * 1992-11-27 1994-06-03 Ensuiko Sugar Refining Co Ltd タキソールのサイクロデキストリン包接物,その製造法と用途
JPH0753396A (ja) * 1993-08-19 1995-02-28 Ensuiko Sugar Refining Co Ltd タキソールのサイクロデキストリン包接物,その製造法および用途
HU213200B (en) * 1993-05-12 1997-03-28 Chinoin Gyogyszer Es Vegyeszet The cyclodextrin or cyclodextrin derivative cluster complexes of taxol, taxotere, or taxus, pharmaceutical preparations containing them and process for their production
DE4414138A1 (de) * 1994-04-22 1995-10-26 Consortium Elektrochem Ind Acylierte gamma-Cyclodextrine
HUT73844A (en) * 1994-11-11 1996-09-30 Chinoin Gyogyszer Es Vegyeszet New taxol complexes and pharmaceutical compositions containing them
CA2163837C (en) * 1994-12-13 1999-07-20 Robert K. Perrone Crystalline paclitaxel hydrates
PL368945A1 (en) * 2001-11-30 2005-04-04 Bristol-Myers Squibb Company Paclitaxel solvates

Also Published As

Publication number Publication date
ZA989779B (en) 1999-04-28
HUP9701945A3 (en) 2000-04-28
JP3656550B2 (ja) 2005-06-08
CA2309326C (en) 2010-12-21
CA2309326A1 (en) 1999-05-20
CN1222321C (zh) 2005-10-12
US20070087999A1 (en) 2007-04-19
WO1999024073B1 (en) 1999-07-08
EP1059942A2 (en) 2000-12-20
KR100607391B1 (ko) 2006-08-02
AU1253899A (en) 1999-05-31
EA200000494A1 (ru) 2000-10-30
PL199652B1 (pl) 2008-10-31
NZ504098A (en) 2003-06-30
HUP9701945A1 (hu) 1999-09-28
CN1281373A (zh) 2001-01-24
JP2001522816A (ja) 2001-11-20
WO1999024073A1 (en) 1999-05-20
US7671042B2 (en) 2010-03-02
DE69839224T2 (de) 2009-04-16
EP1059942B1 (en) 2008-03-05
AR015482A1 (es) 2001-05-02
IL135990A0 (en) 2001-05-20
NO20002165L (no) 2000-07-07
DE69839224D1 (de) 2008-04-17
KR20010031967A (ko) 2001-04-16
HU9701945D0 (en) 1998-01-28
AU742036B2 (en) 2001-12-13
NO20002165D0 (no) 2000-04-27
NO329382B1 (no) 2010-10-04
EA002776B1 (ru) 2002-08-29
PL340505A1 (en) 2001-02-12
ATE387916T1 (de) 2008-03-15

Similar Documents

Publication Publication Date Title
BR9814015A (pt) Processo para preparação de produtos sólidos instantaneamente solúveis para uso farmacêutico, ditos produtos, método de prevenção e tratamento
BR0009578A (pt) Composições de polìmero de dispersão lìquido, sua preparação e seu uso
WO1999021617A3 (en) Allosteric adenosine receptor modulators
ES2195308T3 (es) Composicon farmaceutica de fenofibrato que presenta una biodisponibilidad elevada, y metodo para su preparacion.
BR0012590A (pt) Composto, processo para a preparação do mesmo, formulação farmacêutica, uso de um composto, e, métodos para tratamento ou profilaxia de dor ou desconforto, e para tratamento ou profilaxia de dor neuropática ou central
BRPI9913945B8 (pt) Composição farmacêutica rapidamente atuante para a administração sublingual de um agente farmacêutico para o tratamento de distúrbios agudos
BR0107147A (pt) Composições farmacêuticas de drogas anti-tuberculosas e processo para as suas preparações
ATE146360T1 (de) Gonadotropin enthaltende gefriergetrocknete troepfen
BR9206593A (pt) Partículas especialmente partículas coloidais processo de prepará-las a partir de uma fase cristalina líquida homogênea ou fase L3 composição farmacêutica e uso destas partículas
CN104918927A (zh) 含有至少一种水溶助长剂和至少一种活性化合物的化妆品组合物
NO20100302L (no) Sammensetninger som inneholder organiske forbindelser
US8012495B2 (en) Lotion-treated tissue and towel
BR0016227A (pt) Derivados de adamantano
BR0214243A (pt) Derivado de sulfonamida processo para a preparação de um derivado de sulfonamida e seus sais fisiologicamente aceitáveis, composição farmacêutica e uso de um derivado de sulfonamida
BR0103844A (pt) Sistema de aditivo polimérico múltiplo, processo para produzir o mesmo, composição polimérica, e, processo para produzir a mesma
UY24288A1 (es) Procedimiento para la preparación de una composición de liberación retardada de paroxetina
FI20000172A7 (fi) Itse-emulgoituvan valmisteen muodossa oleva farmaseuttinen koostumus happamia lipoifiilisia yhdisteitä varten
WO2002074056A3 (en) Allosteric adenosine receptor modulators
ITMI932634A1 (it) Composizione farmaceutica per uso topico contenente acido (s)-2-(4- isobutilfenil) propionico
BR0210228A (pt) Composição cosmética, processo para tratamento cosmético dos cabelos e uso de uma composição
EP1671973A3 (en) Allosteric adenosine receptor modulators
DK157689D0 (da) Farmaceutiske piroxicammidler i vandige oploesninger samt fremgangsmaade til fremstilling heraf
AR008355A1 (es) COMPOSICIoN FARMACÉUTICA PARA ADMINISTRACIoN ORAL, USO, CREMA FARMACEUTICA PARA ADMINISTRACIoN TOPICA Y SUSPENSIoN LIQUIDA PARA ADMINISTRACIoN ORAL.
CA2449485A1 (en) Pharmaceutical and/or cosmetic compositions for the treatment of localised adiposities and cellulite
AR026240A1 (es) Empleo de polisiloxanos con grupos de amonio cuaterinario como agentes auxiliares de formulacion y composiciones que les contienen

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Free format text: CYCLOLAB LTD (HU)

B25A Requested transfer of rights approved

Owner name: HEXAL AG (DE)

Free format text: TRANSFERIDO DE: CYCLOLAB LTD.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: DE ACORDO COM O ART. 37, INDEFIRO O PRESENTE PEDIDO, UMA VEZ QUE NAO ATENDE AO REQUISITO DE ATIVIDADE INVENTIVA (ART. 8O COMBINADO COM ART. 13 DA LPI).

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.

B15K Others concerning applications: alteration of classification

Ipc: B82Y 5/00 (2011.01), A61K 9/00 (2006.0